Top

Published in:

01-10-2008 | Original Article

High prevalence of hepatitis B virus pre-S mutation and its association with hepatocellular carcinoma in Qidong, China

Authors: Zhigang Cao, Xin Bai, Xia Guo, Yan Jin, Gengsun Qian, Hong Tu

Published in: Archives of Virology | Issue 10/2008

Abstract

We investigated the frequency and the clinical relevance of hepatitis B virus (HBV) pre-S mutations in Qidong, China. The results showed HBV pre-S mutants were detected in 48.4% (47/97) of patients with HBV infection. Both pre-S deletion and pre-S2 start codon mutations were more frequently found in HCC than in CH patients (51.1% vs. 18.0%, P < 0.01 and 21.2% vs. 8.0%, P = 0.06). In most cases, pre-S mutants coexisted with the wild-type HBV strain. Longitudinal observation clearly revealed that in four of five cases, HBV deletion mutants emerged during the course of HBV infection and eventually became the predominant or exclusive viral population at the stage of HCC. Thus, it was concluded that HBV pre-S mutations were highly prevalent and closely related to HCC in Qidong. Our results also provided direct evidence that pre-S deletion mutants were not acquired from the beginning of infection but arose de novo during the progression of liver disease.

Baumert TF, Barth H, Blum HE (2005) Genetic variants of hepatitis B virus and their clinical relevance. Minerva Gastroenterol Dietol 51:95–108PubMed

Buti M, Rodriguez-Frias F, Jardi R, Esteban R (2005) Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J Clin Virol 34(Suppl 1):S79–S82PubMedCrossRef

Chai N, Gudima S, Chang J, Taylor J (2007) Immunoadhesins containing pre-S domains of hepatitis B virus large envelope protein are secreted and inhibit virus infection. J Virol 81:4912–4918PubMedCrossRef

Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS (2006) High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 130:1153–1168PubMedCrossRef

Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS (2007) Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133:1466–1474PubMedCrossRef

Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, Zhu YR, Chen TY (2006) Trends in the incidence of cancer in Qidong, China, 1978–2002. Int J Cancer 119:1447–1454PubMedCrossRef

Chen JG, Kuang SY, Egner PA, Lu JH, Zhu YR, Wang JB, Zhang BC, Chen TY, Munoz A, Kensler TW, Groopman JD (2007) Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry. Cancer Epidemiol Biomarkers Prev 16:1213–1218PubMedCrossRef

Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association (2007) Guideline on prevention and treatment of chronic hepatitis. Chin Med J 120:2159–2173

Chisari FV, Ferrari C (1995) Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29–60PubMedCrossRef

10.

Choi MS, Kim DY, Lee DH, Lee JH, Koh KC, Paik SW, Rhee JC, Yoo BC (2007) Clinical significance of pre-S mutations in patients with genotype C hepatitis B virus infection. J Viral Hepat 14:161–168PubMedCrossRef

11.

Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, Shiau AL, Su IJ (2001) Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 33:277–286PubMedCrossRef

12.

Fernholz D, Stemler M, Brunetto M, Bonino F, Will H (1991) Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. J Hepatol 13(Suppl 4):S102–S104PubMedCrossRef

13.

Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H (1993) Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 194:137–148PubMedCrossRef

14.

Gao ZY, Li T, Wang J, Du JM, Li YJ, Li J, Lu FM, Zhuang H (2007) Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol 42:761–768PubMedCrossRef

15.

Guo X, Jin Y, Qian G, Xu L, Tu H (2007) Full-geneome sequence analysis of hepatitis B virus isolated from hepatocellular carcinoma in high incidence area Qidong. Tumor in Chinese with English abstract 27:4

16.

Hartmann-Stuhler C, Prange R (2001) Hepatitis B virus large envelope protein interacts with gamma2-adaptin, a clathrin adaptor-related protein. J Virol 75:5343–5351PubMedCrossRef

17.

Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W (2004) Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 25:2023–2032PubMedCrossRef

18.

Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT, Huang W, Chang WC, Chang YS, Chen CC, Lai MD (2004) Endoplasmic reticulum stress stimulates the expression of cyclooxygenase–2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 279:46384–46392PubMedCrossRef

19.

Huy TT, Ushijima H, Win KM, Luengrojanakul P, Shrestha PK, Zhong ZH, Smirnov AV, Taltavull TC, Sata T, Abe K (2003) High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol 41:5449–5455PubMedCrossRef

20.

Klingmuller U, Schaller H (1993) Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol 67:7414–7422PubMed

21.

Kuang SY, Jackson PE, Wang JB, Lu PX, Munoz A, Qian GS, Kensler TW, Groopman JD (2004) Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A 101:3575–3580PubMedCrossRef

22.

Lin CL, Liu CH, Chen W, Huang WL, Chen PJ, Lai MY, Chen DS, Kao JH (2007) Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 22:1098–1103PubMedCrossRef

23.

Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FV (1985) Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl Acad Sci U S A 82:8168–8172PubMedCrossRef

24.

Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P, Chisari FV (1985) Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228:1195–1199PubMedCrossRef

25.

Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z (2002) Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36:1214–1220PubMedCrossRef

26.

Pawlotsky JM (2005) The concept of hepatitis B virus mutant escape. J Clin Virol 34(Suppl 1):S125–S129PubMedCrossRef

27.

Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, Sagliocca L, Pasquali M, Tanzi E, Longo G, Raimondo G (1997) Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 26:495–499PubMedCrossRef

28.

Pujol FH, Devesa M (2005) Genotypic variability of hepatitis viruses associated with chronic infection and the development of hepatocellular carcinoma. J Clin Gastroenterol 39:611–618PubMedCrossRef

29.

Raimondo G, Costantino L, Caccamo G, Pollicino T, Squadrito G, Cacciola I, Brancatelli S (2004) Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J Hepatol 40:515–519PubMedCrossRef

30.

Santantonio T, Jung MC, Schneider R, Fernholz D, Milella M, Monno L, Pastore G, Pape GR, Will H (1992) Hepatitis B virus genomes that cannot synthesize pre-S2 proteins occur frequently and as dominant virus populations in chronic carriers in Italy. Virology 188:948–952PubMedCrossRef

31.

Seifer M, Heermann KH, Gerlich WH (1990) Expression pattern of the hepatitis B virus genome in transfected mouse fibroblasts. Virology 179:287–299PubMedCrossRef

32.

Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, Wang J, Wu Y, Liu G, Zhu Y (1999) Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30:379–383PubMedCrossRef

33.

Sun Z, Ming L, Zhu X, Lu J (2002) Prevention and control of hepatitis B in China. J Med Virol 67:447–450PubMedCrossRef

34.

Suwannakarn K, Tangkijvanich P, Thawornsuk N, Theamboonlers A, Tharmaphornpilas P, Yoocharoen P, Chongsrisawat V, Poovorawan Y (2008) Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. Hepatol Res 38:244–251PubMedCrossRef

35.

Tiollais P, Pourcel C, Dejean A (1985) The hepatitis B virus. Nature 317:489–495PubMedCrossRef

36.

Tong S (2005) Mechanism of HBV genome variability and replication of HBV mutants. J Clin Virol 34(Suppl 1):134–138CrossRef

37.

Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ (2003) Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 163:2441–2449PubMed

38.

Wang HC, Chang WT, Chang WW, Wu HC, Huang W, Lei HY, Lai MD, Fausto N, Su IJ (2005) Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 41:761–770PubMedCrossRef

39.

Yang L, Parkin DM, Li LD, Chen YD, Bray F (2004) Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer 90:2157–2166PubMed

Title: High prevalence of hepatitis B virus pre-S mutation and its association with hepatocellular carcinoma in Qidong, China
Authors: Zhigang Cao
Xin Bai
Xia Guo
Yan Jin
Gengsun Qian
Hong Tu
Publication date: 01-10-2008
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 10/2008
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-008-0176-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2008

Cold co-extraction of hemagglutinin and matrix M1 protein from influenza virus A by a combination of non-ionic detergents allows for visualization of the raft-like nature of the virus envelope

Noroviruses and sapoviruses in pigs in Belgium

The low-virulent African swine fever virus (ASFV/NH/P68) induces enhanced expression and production of relevant regulatory cytokines (IFNα, TNFα and IL12p40) on porcine macrophages in comparison to the highly virulent ASFV/L60

Six novel begomoviruses infecting tomato and associated weeds in Southeastern Brazil

Increased detection of influenza A H16 in the United States

Brugmansia suaveolens mottle virus, a novel potyvirus causing leaf mottling of Brugmansia suaveolens in Brazil

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials